IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

In the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to segment IgAN patients and which drug to use – a question that even nephrologists are having difficulty answering – and what challenges in the disease and its treatment they must still seek to address.

Two significant developments in the field happened in the last few months of 2024. On 5 September, the US...